Table of Contents
What changed
Net operating income rose 8.9% to NZD 130.8m, but operating profit jumped 24.6% to NZD 73.5m, indicating strong pre-impairment operating leverage. Profit before tax rose only 8.8% to NZD 64.9m and NPAT rose 7.8% to NZD 47.5m, implying the gap between operating profit and PBT (circa NZD 8.6m) reflects impairment and other below-the-line charges that were near-zero in HY21. Total assets grew 10.3% to NZD 5,998.9m against equity growth of only 5.6% to NZD 778.2m, so the book expanded faster than capital. Cash rose to NZD 207.7m from NZD 152.8m, while the interim dividend was lifted 37.5% to 5.5 cents per share. Operating cash outflow widened to NZD 142.3m from NZD 5.3m — a normal signature of an expanding non-bank lender funding loan growth, not a working-capital red flag.
What matters
- Segment mix shifted decisively. Reverse Mortgages revenue share rose 2.4pp to 11.7% with segment result up to NZD 12.9m from NZD 9.2m, and Australia contributed NZD 15.5m versus NZD 11.4m. This is consistent with Heartland's stated strategic tilt toward Australian reverse mortgages. Business (the largest segment at 28.5% of revenue, ~76% implied margin) also grew.
- Personal Lending deteriorated sharply. Revenue fell from NZD 8.8m to NZD 5.3m and the segment result collapsed from NZD 6.4m to NZD 1.1m — an implied margin of only 20.7% versus 73%+. This, combined with the re-emergence of impairment charges, is the single clearest drag on earnings quality.
- Payout policy has stepped up ahead of earnings. The interim dividend payout ratio reached 68.1% of NPAT versus 50.0% in HY21, even as ROE moved only marginally from 6.0% to 6.1%. The dividend is comfortably supported by the banking balance sheet, but it is not covered by reported free cash flow given the lender's growth profile.
Expectations
No forward guidance, forward-work balance or medium-term target was disclosed in the extracted materials, so run-rate judgements are limited to seasonality. FY21 was slightly second-half weighted on NPAT (HY21 contributed 50.7% of FY21 NPAT) and roughly even on revenue (47.8%). Annualising HY22 revenue gives NZD 261.6m, about 4.2% above the FY21 anchor of NZD 251.2m; annualising HY22 NPAT at NZD 95.0m would be about 9.2% above FY21's NZD 87.0m. A return to typical second-half weighting would imply a mid-to-high single digit FY22 NPAT beat of FY21, which is materially below the headline operating profit growth rate of 24.6%.
Quality of result
Pre-impairment earnings look genuinely stronger: net operating income grew 8.9%, but operating profit expanded at nearly 3x that rate, pointing to positive jaws. However, the step-down from 24.6% operating profit growth to 7.8% NPAT growth is driven by a roughly NZD 8.6m impairment-style charge that did not recur from HY21 — this reduces the durability of the headline operating line. The effective tax rate was broadly stable (26.8% vs 26.1%), so tax is not distorting the read. The large negative operating cash flow is structural for a lender growing its book and should not be interpreted as a cash-quality issue; capex at NZD 8.6m (up from NZD 4.3m) is a more relevant efficiency signal but is still modest at 6.6% of revenue. The release references an "underlying" NPAT of NZD 47.1m that excludes unspecified one-offs — without an extracted reconciliation, the underlying-to-reported bridge is not testable.
Unresolved
- What drove the NZD 8.6m gap between operating profit and PBT — specifically, how much is impairment provisioning versus other non-operating items, and which segments carried it?
- Why did Personal Lending revenue and segment result fall so sharply, and is the 20.7% implied margin a new baseline or a one-period distortion?
- What are the itemised one-offs inside the underlying NPAT of NZD 47.1m?
- With total liabilities up 11.1% against 5.6% equity growth and current-period gross borrowings not disclosed, what is the true trajectory of funding mix and capital headroom?
- Is the 37.5% dividend step-up a signal of sustained higher payout, or calibrated to a strong reported period?
This briefing cannot assess regulatory capital ratios, credit-quality trends (arrears, provisioning coverage), NIM dynamics, or FX translation impact from Australia, as none were present in the extracted data.
Key metrics
| Metric | HY22 | HY21 | Change |
|---|---|---|---|
| Revenue | $130.8m | $120.1m | +8.9% ↑ |
| Net profit after tax | $47.5m | $44.1m | +7.8% ↑ |
| Net cash inflow from operating activities | −$142.3m | −$5.3m | -2568.5% ↓ |
| Interim dividend per share | 5.5c | 4.0c | +37.5% ↑ |
| Operating profit | $73.5m | $59.0m | +24.6% ↑ |
| Cash and cash equivalents | $207.7m | $152.8m | +35.9% ↑ |
| Total assets | $5998.9m | $5438.0m | +10.3% ↑ |
Reference: annolyse.ai/briefings/hgh-hy22
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Motor | $36.4m | $33.0m | $31.9m | +0.4pp |
| Reverse Mortgages | $15.3m | $11.2m | $12.9m | +2.4pp |
| Personal Lending | $5.3m | $8.8m | $1.1m | -3.3pp |
| Business | $37.3m | $33.0m | $28.3m | +1.1pp |
| Rural | $15.5m | $15.5m | $13.1m | -1.1pp |
| Australia | $21.0m | $18.2m | $15.5m | +0.9pp |
Reference: annolyse.ai/briefings/hgh-hy22
Analytical metrics
| Metric | HY22 | HY21 | Context |
|---|---|---|---|
| PBT growth | +8.8% | — | — |
| Effective tax rate | 26.8% | 26.1% | — |
| FCF pre-lease | −$150.9m | −$9.7m | −$141.2m |
| FCF / NPAT | -317.6% | -21.9% | complementary conversion metric |
| Capex % revenue | 6.6% | 3.6% | — |
| Capex | −$8.6m | −$4.3m | −$4.3m |
| Gross borrowings | — | $1374.0m | — |
| Payout ratio vs NPAT | 68.1% | — | — |
| ROE (annualised) | 6.1% | 6.0% | Strengthening |
| HY21 share of FY21 revenue | 47.8% | — | Other half was 52.2% |
| HY21 share of FY21 NPAT | 50.7% | — | Other half was 49.3% |
| Profit from continuing operations | $47.5m | $44.1m | +$3.4m |
Reference: annolyse.ai/briefings/hgh-hy22
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.